Genprex, Inc. (NASDAQ: GNPX) regains Nasdaq minimum bid compliance
Rhea-AI Filing Summary
Genprex, Inc. reported that a Nasdaq Hearings Panel has formally determined the company has regained compliance with the Nasdaq Capital Market $1.00 Minimum Bid Price requirement under Listing Rule 5550(a)(2). This follows the Panel’s earlier decision granting Genprex an exception to work toward compliance.
The company must now maintain a closing bid price at or above $1.00 for every trading day through December 7, 2026, which is the full extent of the Panel’s discretion on this matter. The Panel will retain jurisdiction over Genprex until that date. If the company becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it will have seven calendar days to present a plan to cure the deficiency, after which the Panel may either permit additional time for compliance or move to delist the company.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 3.01, 9.01
2 items
Item 3.01
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Securities
The company received a delisting notice or transferred its listing to a different exchange.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Minimum Bid Price Requirement: $1.00 per share
Panel Jurisdiction End Date: December 7, 2026
Compliance Notification Date: August 4, 2026
+1 more
4 metrics
Minimum Bid Price Requirement
$1.00 per share
Nasdaq Listing Rule 5550(a)(2) minimum closing bid price
Panel Jurisdiction End Date
December 7, 2026
Date until which the Nasdaq Hearings Panel retains jurisdiction
Compliance Notification Date
August 4, 2026
Date Genprex was formally notified it regained bid-price compliance
Response Period for New Deficiencies
seven calendar days
Time allowed to present a plan if another listing rule is breached
Key Terms
Nasdaq Hearings Panel, Minimum Bid Price requirement, Nasdaq Listing Rule 5550(a)(2), continued listing
4 terms
Nasdaq Hearings Panel regulatory
"on July 29, 2026, the Nasdaq Hearings Panel (the “Panel”) notified"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.
Minimum Bid Price requirement regulatory
"compliance with the $1.00 Minimum Bid Price requirement set forth"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
Nasdaq Listing Rule 5550(a)(2) regulatory
"requirement set forth in Nasdaq Listing Rule 5550(a)(2)"
continued listing regulatory
"Notice of Delisting or Failure to Satisfy a Continued Listing Rule"
When a stock receives a "continued listing," it means the exchange has decided the company’s shares will remain tradable on that market after a review or challenge, often because the company met certain requirements or corrective steps. For investors this matters because continued listing preserves liquidity and access to buy or sell the stock—think of it as a store passing an inspection so customers can keep shopping rather than being forced to close.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did Genprex (GNPX) disclose about its Nasdaq listing status?
Genprex disclosed it has regained compliance with Nasdaq’s $1.00 Minimum Bid Price rule. A Nasdaq Hearings Panel confirmed compliance but will retain jurisdiction over the company’s listing until December 7, 2026.
What is the minimum bid price requirement affecting Genprex (GNPX)?
Genprex must maintain a closing bid price of at least $1.00 per share. This requirement is set by Nasdaq Listing Rule 5550(a)(2) and applies to every trading day through December 7, 2026.
How long will the Nasdaq Hearings Panel oversee Genprex (GNPX)?
The Nasdaq Hearings Panel will maintain jurisdiction over Genprex’s listing until December 7, 2026. During this period, the Panel monitors compliance with the bid-price rule and any other Nasdaq listing standards.
What happens if Genprex (GNPX) violates another Nasdaq listing rule?
If Genprex becomes non-compliant with any other Nasdaq listing rule before December 7, 2026, it has seven calendar days to explain its plan to cure the deficiency. The Panel may then grant an exception or move to delist the company.
Which specific Nasdaq rule did Genprex (GNPX) regain compliance with?
Genprex regained compliance with Nasdaq Listing Rule 5550(a)(2), the $1.00 Minimum Bid Price requirement for continued listing on the Nasdaq Capital Market, as confirmed by the Nasdaq Hearings Panel.